Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 [Yahoo! Finance]
Profusa, Inc. (PFSA)
Company Research
Source: Yahoo! Finance
BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany. The presentation will discuss additional insights into tissue oxygen monitoring of PAD patients from Profusa's US-based pilot clinical study on Wednesday, January 28 th , 2026, 9:45am CET at the Trade Fair Leipzig, Hall 2. “Our proprietary Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within the body, intended for use both in the clinic and at home,” said Ben Hwang, Ph.D., Profusa's Chairman and CEO. “With positive feedback from our U.S.-based clinical study evaluating our pioneering Lumee technology wi
Show less
Read more
Impact Snapshot
Event Time:
PFSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFSA alerts
High impacting Profusa, Inc. news events
Weekly update
A roundup of the hottest topics
PFSA
News
- Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 [Yahoo! Finance]Yahoo! Finance
- Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025GlobeNewswire
- Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026GlobeNewswire
- Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025GlobeNewswire
- Profusa (NASDAQ:PFSA) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e+)" rating on the stock.MarketBeat